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1. Introduction
3,4-Methylenedioxy-N-methylamphetamine, more commonly
called MDMA or ‘‘ecstasy’’, is a synthetic drug similar in structure
to methamphetamine (Fig. 1). It is an illegal drug with stimulatory
and psychedelic effects, and is commonly associated with rave and
trance clubs. It is believed that MDMA inhibits serotonin reuptake
in synapses, and also causes release of more serotonin into the
synapse. In addition, dopamine, acetylcholine, and norepinephrine
release is induced, along with the release of several other
hormones [1]. Its effects cause it to behave as an entactogen,
making it popular among all age groups. Illicit use of MDMA
became popular in the 1980s, resulting in its assignment as a
Schedule I controlled substance. Although there are many
metabolites formed from MDMA, roughly 65% of the dose is
eliminated from the body unchanged in urine [2].
There has been a considerable amount of research done on
MDMA found in urine. Current analytical techniques for detection of
MDMA and its metabolites in urine and other bodily fluids include
HPLC, GC–MS, LC–MS, capillary electrophoresis (CE), and immu-
noassays. In a review by Butler and Guilbault [3], sample preparation
plays an important role for the identification of MDMA. Methods
such as cleavage of conjugates, liquid–liquid extraction, solid phase
extraction, and derivatization procedures including UV spectro-
scopy and using fluorogenic reagents, although very time consum-
ing, have facilitated the identification of MDMA in biological
matrices. MDMA concentrations in fatal and non-fatal cases do vary.
Plasma concentrations of 0.424 mg/L from a 150 mg dose of MDMA
resulted in severe hyperthermia and death, whereas another patient
ingested 42 pills and registered a plasma concentration of 7.72 mg/L
and was asymptomatic [4]. A more recent publication by Garcia-
Repetto et al. [2] also reported finding cases where consumers have
survived a 40–50-tablet overdose without any symptoms, whereas
other users have died after 1–3 tablets with MDMA serum
concentrations between 0.1 and 0.4 mg/L.
NMR spectroscopy is a powerful tool to analyze chemical
structures and can be used to analyze biological fluids for the
diagnosis of acute poisoning and drug overdoses [5] without the
need for separation and/or derivatization steps. Studies by
Imbenotte et al. [6] used NMR to identify and quantitate levels
of various xenobiotics causing poisoning, such as salicylate,
valproic acid, paraquat, and tetrahydrofuran. Work done by Wahl
et al. [7] investigated 1H NMR as a tool for diagnosis and
quantification of poisoning with methanol and ethylene glycol. Not
only did the NMR technique make a rapid diagnosis possible,
requiring only a small sample without derivatization or extraction
required, but it also allowed for qualitative analysis as well as
reliable quantification. Another example is the work on GHB
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(gamma hydroxybutyric acid) and GBL (gamma hydroxybutyr-
olactone), increasingly popular drugs of abuse, which were
analyzed with 1H NMR in a study by Del Signore et al. [8].
However, there has not been any work conducted using NMR to
detect MDMA in urine samples. In this paper, we propose an NMR
procedure for the analysis of urine from 5 cases of MDMA
intoxication using 1H NMR and a new water suppression technique
PURGE (Presaturation Utilizing Relaxation Gradients and Echoes).
2. Materials and methods
2.1. Biological samples
Samples of urine from MDMA users were collected in this project. In accordance
with an IRB-approved protocol, the urine was donated purely on a voluntary basis.
Additionally, donors were asked to record the estimated time between MDMA dosage
and urine collection. Since MDMA is classified as a schedule 1 controlled substance by
the DEA under the Controlled Substances Act, volunteers were completely anony-
mous with no physical evidence linking them to the project. Urine sample were
collected and immediately frozen at 20 8C until required for NMR measurements.
2.2. Proton NMR spectroscopy
All data (1H NMR) were collected on a Bruker 500 MHz NMR spectrometer (Bruker
BioSpin, Billerica, MA) at the Chemistry Department of Columbia University.
Depending on the estimated concentration of the analytes observed, data collection
differed, because better signal to noise ratios are obtained by an increasing number of
scans. A trial-and-error approach was used to determine the amount of scans needed
for different samples.
One-dimensional spectra were obtained using the water suppression technique
PURGE (Presaturation Utilizing Relaxation Gradients and Echoes) described by
Simpson et al. to suppress the signal from water [9]. The experiment produces flat
baselines, excellent phase properties, and highly selective suppression that is equal or
superior to that produced by commonly used sequences such as WATERGATE, WET, or
excitation sculpting. Except for the 4.5–4.7 ppm range of the water signal, the
excitation profile of PURGE is uniform over the full proton spectrum and does not
suffer from the periodic null ‘‘sidebands’’ that plague some techniques. The uniform
excitation allows the use of quantitative calibration standards with chemical shifts
that are well separated from the MDMA peaks. PURGE has the further significant
advantage that the only parameter that needs adjustment is the presaturation power,
making it easy to implement even for non-spectroscopists and, thus, it could be easily
adapted to a clinical setting. In practice, little or no adjustment of the presaturation
power is necessary once the experiment has been optimized.
Five hundred microlitres of each sample was introduced into a 5 mm tube with a
coaxial capillary tube containing a solution of 3-trimetyhylsilyl 2,20 ,3,30-tetra-
deuteropropionic acid (TSP-d4) providing an internal field frequency lock and
reference for proton chemical shifts (d = 0 ppm).
2.3. Spectrum of MDMA in D2O
A 1H NMR Spectrum of MDMA in D2O was recorded and is shown in Fig. 2.
Chemical shifts, coupling constants are listed in Table 1. Diastereotopic protons C
are designated as C1 and C2. MDMA is supplied as a racemic mixture, however, it is
not possible to resolve the two enantiomers using NMR spectroscopy as both
enantiomers give identical spectra.
2.4. Quantification by proton NMR spectroscopy
A concentration gradient consisting of nine solutions in control urine each with a
volume of 500 mL were prepared. Concentrations of MDMA reported are expressed in
mg/mL of the free base. Serial dilutions of 1.00, 0.8, 0.5, 0.2, 0.1, 0.08, 0.05, 0.02, and
0.01 mg/mL of MDMA, in the blank urine were analyzed using 1H NMR. Concentrations
of 1.00, 0.8, 0.5, 0.2, 0.1, and 0.08 mg/mL were scanned 128 times. Concentrations of
0.05 mg/mL were scanned 512 times. Concentrations of 0.02 mg/mL were scanned
2048 times. Concentrations of 0.01 mg/mL were scanned in overnight experiments,
allowingfor a rangefrom10,000 to12,000scans.Fig. 3 isa representativespectrumofa
sample with a 0.1 mg/mL concentration of MDMA. Boxed regions are caused by MDMA
Fig. 2. Spectrum of 1 mg/mL MDMA in D2O, 16 scans.
Fig. 1. Structure of 3,4-methylenedioxy-N-methylamphetamine.
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Fig. 3. 0.1 mg/mL MDMA in spiked control urine, 128 scans.
Fig. 5. Aromatic MDMA peaks area to TSP-d4 peak area ratio vs. concentration of
MDMA in urine samples.
Table 1
Chemical shifts, coupling constants, number of protons, and peak multiplicity of MDMA in D2O.
Proton Chemical shift (ppm) Chemical shift (Hz) J coupling constant (Hz) # protons Peak multiplicity
A 1.13 566.94 6.6 3 d
H 2.55 1273.64 – 3 s
C1 2.71 1353.25 J1 = 14 2 dd
J2 = 7.6
C2 2.83 1414.75 J1 = 14 dd
J2 = 6.6
B 3.34 1672.35 7 1 Apparent
sextet
E 6.65 3324.90 J1 = 7.9 1 dd
J2 = 1.3
F 6.71 3354.70 1.4 1 d
D 6.75 3375.42 7.9 1 d
Fig. 4. 0.1 mg/mL MDMA in spiked control urine. Aromatic region.
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peaks, and the regions outside the boxes are from the urinary metabolites. As expected,
the 1.0–4.0 ppm regionisdifficult tointegrateaccuratelydue tointerference byurinary
metabolites. In this region and at lower concentrations some of the drug peaks are
completely masked by metabolite peaks. Aromatic peaks (Fig. 4, protons D, F, and E) in
the 6.6–7.0 ppm range were chosen for integration. Fig. 5 shows the calibration curve
generated fromthefollowing plotting: [area fromthe MDMAaromaticpeaks/areafrom
the internal standard peak] vs. drug concentration.
2.5. Standard deviation, limit of detection and limit of quantitation
In any analytical method, it is important to determine the limit of detection
and limit of quantitation. These two limits, along with variance and standard
deviation calculations can be used to define the sensitivity of a test. To
determine the standard deviation, seven independent urine samples spiked with
MDMA at a concentration of 0.05 mg/mL were run. Statistical analysis of the
seven different spiked urine samples of MDMA was performed based on the
results of integrating the area of the aromatic peaks vs. the area of the internal
standard peak in their NMR spectra. For the MDMA samples, relative standard
deviation was calculated to be 0.56%.
As for the LOD, the very nature of NMR makes it impossible to determine as it
depends on the amount of scans used for the experiment. However, in this study we
have limited the experimental time to overnight experiments, allowing for a range
from 10,000 to 12,000 scans. This experimental time allows for a limit of
quantification in the 0.01 mg/mL concentrations range.
Fig. 6. (a) Sample 1 256 scans. Superimposed in gray is the spectrum of MDMA spiked urine (0.50 mg/mL). (b) Top: blow up of different regions (6.7–6.9; 2.75–2.5; 1.6–
1.15 ppm) of the MDMA spiked urine spectrum, bottom: blow up of the same regions (6.7–6.9; 2.75–2.5; 1.6–1.15 ppm) of the spectrum from sample 1.
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3. Results and discussion
The five samples of urine donated by volunteers were analyzed
with different numbers of scans based on a trial-and-error method.
The number of scans necessary for each sample is indicated in
Table 2. Presence of MDMA was based on the observed peak
pattern in the 6.7–7.0 ppm region along with the presence of the
peak caused by the methylenic protons G which appear on
the trailing edge of the urea peak. The presence of the peaks from
the methyl protons (A and H) of MDMA in the spectra helped
confirm the results. Fig. 6a shows the spectrum of sample 1.
Superimposed in gray is the spectrum of MDMA spiked urine
(0.50 mg/mL). Spectra for the other samples can be seen in the
supportive information documents. In all spectra, we consistently
observed the peak for proton G as well as all the peaks in the
aromatic region for protons D, E and F. However, for samples 2, 3
and 5 a broadening of the peak responsible for the signal of proton
F was observed as well as a small extra peak around 6.83 ppm
probably resulting from the presence of metabolites. The signals
for the diastereotopic protons C were only observed distinctively in
the case of sample 1. Proton B was masked by endogenous
compounds in all cases. The peak at d = 2.69 from proton H could be
observed in all cases. However, because it partially overlaps with
the citrate peaks it is not a reliable indication of the presence of
MDMA in the sample. Finally, a doublet at d = 1.27 ppm from
protons A was observed in all spectra but because of the crowded
nature of this region of the spectrum, this doublet cannot be
considered for positive identification either.
For all samples, a baseline correction was performed. Quanti-
tative analysis was performed by calculating the ration between
the area of the aromatic peaks (D, F, and E) and the area of the TSP-
d4 peak and using the calibration curve previously established.
Table 2 summarizes the results of the sample analysis.
In all cases, NMR analysis of the samples confirmed the
presence of MDMA. The concentration of the drug in urine varied
from 0.029 to 0.082 mg/mL. There was no observed correlation
between the time elapsed between the ingestion of MDMA and the
collection of the sample. In Table 2, even samples collected in the
same 8 h timeframe after dosage had a wide range of concentra-
tions. Sample 2 had an estimated concentration of 0.029 mg/mL
whereas sample 3, had a far higher concentration at 0.078 mg/mL.
This is not surprising as the subject’s metabolic rates, along with
the amount of drug and fluids consumed would affect amounts
excreted. In addition, it is difficult to confirm how much of the drug
was ingested due to the clandestine process used to manufacture
MDMA. As a result, the pills may not always be pure, as they are
commonly cut with other substances. Furthermore, each volunteer
may not have consumed the same brand of pill or may have
ingested a different number of pills.
These results suggest the 1H NMR spectroscopy could provide a
convenient tool for the rapid detection of MDMA in human urine.
This method presents the advantage of a rapid diagnosis with little
urine needed and no sample preparation. Furthermore, in the
concentration range studied, quantitative data can be collected and
samples were analyzed within 20–30 min. In an emergency clinical
context, the diagnosis problem could be at least partially solved if a
rapid identification procedure for MDMA was available even is the
dose is not related to toxicity. The NMR method should be useful
for such a rapid identification. Furthermore, the NMR method
could also be useful in a forensic context for the following reasons:
the magnitude of the exposure to MDMA could be assessed via
quantification by the NMR technique and it is also a non-
destructive method.
The limitation of using NMR for the identification of MDMA is
that at lower concentrations, the presence of small amounts of
metabolites or other therapeutic agents can interfere. In that case,
the quantification procedure can be difficult. Two-dimensional
sequences may be used in that case. When signal overlap in the 1H
dimension precludes quantitation, 2D carbon-proton spectra, such
as HSQC, can resolve the overlap due to the greater dispersion
available in the carbon dimension. Often analytes with overlapped
proton spectra will have distinguishable cross peaks in an HSQC
spectra. The principles of quantitative HSQC spectra have been
demonstrated [10] and its application to MDMA is the subject of
future work.
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1 6 h MDMA 0.082 256
2 8 h MDMA 0.029 579
3 8 h MDMA 0.078 128
4 7 h MDMA 0.042 400
5 18 h MDMA 0.045 526
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